Clinical safety, immunogenicity and efficacy of a therapeutic vaccine that combines peptides mimicking antigen receptors on autoimmune B and T cells associated with myasthenia gravis.

 

     img2 home

 

Update on Myasterix study: Safety report summary

The Myasterix Phase 1b study (EudraCT 2015-002880-41) is followed by a Data Review Committee which conducted a formal safety data review in August and then in December 2016.

Read more

Belgian investment & collaboration forum 22 November 2016

Nicolas Havelange and Stéphane Huberty, participated in the Belgian investment and collaboration forum on the 22nd of November 2016

Read more

MYASTERIX progress
September 2016

The 3rd MYASTERIX general meeting took place in Paris on 22-23 September 2016. It was the opportunity for the partners to present and discuss the progress made so far, at over halfway through the project, since the start of the project in 2013.

Read more

 


               



2016 BIO International Convention
June 6-9th, 2016

CURAVAC participated in BIO2016 on 6-9 June 2016

Webinar MYASTERIX 
June 1st, 2016 

The Belgian and Dutch patients associations on Myasthenia Gravis organised a webinar (in Dutch) on the clinical trial of the therapeutic vaccine developed in MYASTERIX project. The webinar took place the 1st June 2016 from 18.00 to 19.00 CET. 

To view the webinar:

https://www.youtube.com/watch?v=jxXdAnz7ZsQ

More info

Start of the clinical study

The phase 1b study has started at the Antwerp University Hospital (Belgium) and is currently recruiting participants.

More info

eu-fev2014-2

MYASTERIX is a 5-year European Collaborative Project supported by the European Commission under the Health Cooperation Work Programme of the 7th Framework Programme under the Grant Agreement nº 602420.

Follow us on twitter: @Myasterix1

20160923 113948